血管抑制剂
医学
临床试验
血管内皮生长因子受体
药理学
贝伐单抗
内科学
化疗
标识
DOI:10.2174/1389450121666200428101738
摘要
This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. Results of clinical trials and the advantages of each drug compared to the available molecules are discussed in detail.
科研通智能强力驱动
Strongly Powered by AbleSci AI